Pharmacology/ Therapeutics News for January 2013

Pharmacology/ Therapeutics News Archive

Researchers discover promising prognostic marker for aggressive breast cancer Researchers discover promising prognostic marker for aggressive breast cancer

Cleveland - A team of researchers led by Goutham Narla, MD, PhD, at Case Western Reserve University School of Medicine and University Hospitals Case Medical Center, and collaborators at the Mount Sinai School of Medicine and Erasmus Medical Center, have discovered a gene variant that drives the spread of breast cancer. Published in Science Translational Medicine the study lays the early foundation for predicting which breast cancer patients may develop more aggressive disease and for designing more effective treatments.

Launch of trial of ‘master switch’ drug to treat several cancer types Launch of trial of ‘master switch’ drug to treat several cancer types

Cancer Research UK and its commercial arm Cancer Research Technology (CRT) are launching a trial of an experimental drug shown to simultaneously block many enzymes that control cancer cell growth and death. The ‘master-switch’ experimental drug, owned by Astex Pharmaceuticals, could potentially treat a range of cancer types.

Crescendo biologics announces the Crescendo Mouse Crescendo biologics announces the Crescendo Mouse

Crescendo Biologics Limited (Crescendo) announces the Crescendo Mouse, a breakthrough in antibody fragment technology which allows the efficient generation of high-quality fully human single domain antibody VH fragments from a transgenic mouse.

Terbium: a new “Swiss Army knife” for Nuclear Medicine Terbium: a new “Swiss Army knife” for Nuclear Medicine

A unique collaboration between the Paul Scherrer Institute, CERN’s ISOLDE facility, and the Institut Laue-Langevin, has published preclinical study results for a newly developed set of tumour-targeting radiopharmaceuticals.

Researchers identify a new class of drugs, capable of inhibiting the proliferation of various cancer cells Researchers identify a new class of drugs, capable of inhibiting the proliferation of various cancer cells

A pharmacological intervention directed against the proliferation of cancer cells is at the centre of a study conducted by researchers of the Drug Discovery and Development (D3) department of the Istituto Italiano di Tecnologia (IIT), based in Genoa (Italy), published on the International journal Scientific Reports, with the title “Discovery of highly potent acid ceramidase inhibitors with in vitro tumor chemosensitizing activity”.